This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Sloane JP, Lwin KY, Gore ME, Powles RL, Smith JF . Disturbance of blood-brain barrier after bone-marrow transplantation. Lancet 1985; 2: 280–281.
Hinchey J, Chaves C, Appignani B, Breen J, Pao L, Wang A et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med 1996; 334: 494–500.
Kwon S, Koo J, Lee S . Clinical spectrum of reversible posterior leukoencephalopathy syndrome. Pediatr Neurol 2001; 24: 361–364.
Sabry W, Le Blanc R, Labbe AC, Sauvageau G, Couban S, Kiss T et al. Graft-versus-host disease prophylaxis with tacrolimus and mycophenolate mofetil in HLA-matched nonmyeloablative transplant recipients is associated with very low incidence of GVHD and nonrelapse mortality. Biol Blood Marrow Transplant 2009; 15: 919–929.
Chakrabarti S, Mautner V, Osman H, Collingham KE, Fegan CD, Klapper PE et al. Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery. Blood 2002; 100: 1619–1627.
Pham TT, Burchette JL Jr, Hale LP . Fatal disseminated adenovirus infections in immunocompromised patients. Am J Clin Pathol 2003; 120: 575–583.
Woods LW, Swift PK, Barr BC, Horzinek MC, Nordhausen RW, Stillian MH et al. Systemic adenovirus infection associated with high mortality in mule deer (Odocoileus hemionus) in California. Vet Pathol 1996; 33: 125–132.
Junna MR, Rabinstein AA . Tacrolimus induced leukoencephalopathy presenting with status epilepticus and prolonged coma. J Neurol Neurosurg Psychiatry 2007; 78: 1410–1411.
Teh BW, Harrison SJ, Worth LJ, Thursky KA, Slavin MA . Infection risk with immunomodulatory and proteasome inhibitor-based therapies across treatment phases for multiple myeloma: A systematic review and meta-analysis. Eur J Cancer 2016; 67: 21–37.
Kim SJ, Kim K, Kim BS, Lee HJ, Kim H, Lee NR et al. Bortezomib and the increased incidence of herpes zoster in patients with multiple myeloma. Clin Lymphoma Myeloma 2008; 8: 237–240.
Chanan-Khan A, Sonneveld P, Schuster MW, Stadtmauer EA, Facon T, Harousseau JL et al. Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol 2008; 26: 4784–4790.
Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487–2498.
Yokose N, Hirakawa T, Inokuchi K . Adenovirus-associated hemorrhagic cystitis in a patient with plasma cell myeloma treated with bortezomib. Leuk Res 2009; 33: e106.
LeBlanc R, Ahmad I, Terra R, Landais S, Sebag M, Lemieux-Blanchard E et al. Bortezomib consolidation after nonmyeloablative allogeneic stem cell transplantation leads to a high incidence of immunophenotypic complete response in young and/or high-risk multiple myeloma patients. Blood 2016; 128: 2306.
Wold WS, Toth K . New drug on the horizon for treating adenovirus. Expert Opin Pharmacother 2015; 16: 2095–2099.
Acknowledgements
This work was supported by the Université de Montréal Maryse and William Brock Chair in Applied Research into Stem Cell Transplantation and by Myeloma Canada Chair.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Claveau, JS., LeBlanc, R., Ahmad, I. et al. Cerebral adenovirus endotheliitis presenting as posterior reversible encephalopathy syndrome after allogeneic stem cell transplantation. Bone Marrow Transplant 52, 1457–1459 (2017). https://doi.org/10.1038/bmt.2017.154
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2017.154
This article is cited by
-
Outcomes in newly diagnosed young or high-risk myeloma patients receiving tandem autologous/allogeneic transplant followed by bortezomib maintenance: a phase II study
Bone Marrow Transplantation (2022)
-
Adenovirus diseases: a systematic review and meta-analysis of 228 case reports
Infection (2021)
-
Bortezomib/immunosuppressants
Reactions Weekly (2020)